Comment on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: Results of the GETUG-AFU V05 VESPER trial
机构:[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院[2]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院[3]Robotic Minimally Invasive Surgery Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, 610072, China四川省人民医院[4]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院
This work was supported by the National Natural Science Foundation
of China (Grant number: 81500522) and Science & Technology
Department of Sichuan Province (Grant number: 2020YFS0090,
2020YFS0046).
第一作者机构:[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China
通讯作者:
推荐引用方式(GB/T 7714):
Ye Jian-Jun,Ren Shang-Qing,Bao Yi-Ge.Comment on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: Results of the GETUG-AFU V05 VESPER trial[J].ASIAN JOURNAL OF SURGERY.2023,46(2):1163-1164.doi:10.1016/j.asjsur.2022.08.026.
APA:
Ye Jian-Jun,Ren Shang-Qing&Bao Yi-Ge.(2023).Comment on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: Results of the GETUG-AFU V05 VESPER trial.ASIAN JOURNAL OF SURGERY,46,(2)
MLA:
Ye Jian-Jun,et al."Comment on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: Results of the GETUG-AFU V05 VESPER trial".ASIAN JOURNAL OF SURGERY 46..2(2023):1163-1164